|The ensuing logic was presented September 6, 2007 during a Urology Grand Rounds Lecture, September 6, 2007 at UCLA/Harbor General Hospital. The material is based on 4 peer-reviewed publications:
1. Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol. 2006 Oct;176(4 Pt 1):1299-306.
2. Marks LS. Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease. Curr Urol Rep. 2006 Jul;7(4):293-303.
3. Marks LS. Benign Prostatic Hyperplasia Disease: Is Prevention Feasible? Weill Medical College of Cornell University Reports on Men’s Urological Health Vol 1-4.
4. Marks LS: Treatment of men with minimally symptomatic benign prostatic hyperplasia—PRO: the argument in favor. Urology 2003;62:781-783. & Kaplan SA: Medical Therapy For Aysmptomatic Men With Benign Prostatic Hyperplasia: CON: Primum Non Nocere. Urology 2003;62:784-5.